Evaluation of diagnostic value of n-terminal pro brain natriuretic peptide in pleural fluid with cardiac origin by باباپور, بهزاد et al.
                                  International Journal of Community Medicine and Public Health | March 2018 | Vol 5 | Issue 3    Page 912 
International Journal of Community Medicine and Public Health 
Babapour B et al. Int J Community Med Public Health. 2018 Mar;5(3):912-916 
http://www.ijcmph.com pISSN 2394-6032 | eISSN 2394-6040 
Original Research Article 
Evaluation of diagnostic value of n-terminal pro brain natriuretic 
peptide in pleural fluid with cardiac origin 
Behzad Babapour
1
, Mohammad Mirzaaghazadeh
1
, Bita Shahbazzadegan
2
*, Hadi Mohsenifar
3
, 
Alireza Mohammadzadeh
4
, Bijan Zamani
1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Pleural cavity is covered by two screens: visceral pleural 
that covered lung and the parietal pleura covering the 
chest wall and diaphragm. Liquid and protein entered to 
this space in normal mode via the systemic circulation 
and absorbed by the lymphatic vessels of parietal pleura. 
Pleural pressure lower than atmospheric pressure and this 
cause the lungs to inflate. Because of permeable nature of 
mesothelial cells layer, extra fluids can enter to this low 
pressure and wide space. Therefore, the pleuraleffusions 
are common and havedifferent causes. These 
accumulations can caused by pleural diseases or pectoral 
and ventral organs. Its annual incidence is about 1.5 
million in US. One third of them come from heart failure. 
ABSTRACT 
 
Background: Pleural effusion is a common finding in patients. For a long time, a light criterion is used to analysis of 
pleural effusion for separation of transudative from exudative fluid. Sensitivity of light criteria is very high to 
determine exudative pleural effusion (98%). However, the ability of these criteria for ruling out of transudative 
effusions is low. For this reason, this study was carried out to determine the level of NT-proBNP in pleural fluid.  
Methods: A descriptive-analytic study was carried out on 21 patients with complaints of shortness of breath and 
diagnosis of pleural effusion. Pleural fluid was tapped in these patients and the following tests were performed: LDH, 
total protein, albumin, cell count, cell differentiation, cytology for malignant cells, ADA, smear for AFB, gram smear 
and culture.The results of all experiments were analyzed using SPSS V16.  
Results: Mean age of participants was 65 years. Male and female frequencies were 52.4 and 47.6, respectively. 33.3% 
of patients had CHF, 28.5% TB, 19.4% malignancy, 4.76% hydatid, and the rest left without diagnosis. A pleural 
fluid in 66.7% of participants was exudative and in 33.3% was transudative. The levels of NT-proBNP (Pg/ml) in 
serum and pleural fluid of patients with CHF were 11288.42 and 11036.81, but in malignant patient were 1721.68 and 
713.59, respectively, and the levels of NT-proBNP in serum and pleural fluid in TB patient were 2429.30 and 
2810.08, respectively. Also, there was no significant difference between the levels of serum and pleural effusion NT-
proBNP in transudative and exudative fluid but the level of NT-proBNP was significantly higher in CHF patients 
compared to others.  
Conclusions: The results showed that the levels of NT-proBNP in serum and pleural fluid of cardiac patients are 
higher than other patients, but no significant difference in NT-proBNP between transudative and exudative pleural 
effusion.  
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Determining the cause of pleural effusion requires 
strategies such as taken disease history, pleural fluid 
analysis and potentially invasive procedure of pleural 
tissue biopsy.Clinical History is very importantto 
diagnosis of effusion caused by heart failure. However, it 
is not very accurate, alone and often diagnose the cause 
of pleural fluid is a big headache for health care 
providers.
1
 The criteria of light is used to analysis of 
pleural fluid for differentiate transudative from exudative 
liquids. These criteria are including: protein ratio of 
pleural fluid to serum ≤0.5, pleural fluid lactate 
dehydrogenase (LDH) ratio of pleural fluid to serum ≤0.6 
and LDH level of pleural fluid equal to or less than two-
thirds of the maximum normal serum LDH. If all of these 
criteria are true the liquid is transudative and if at least 
one of them is not satisfied it will be exudative.
2
 The 
sensitivity of Light criteria to specify the exudative 
pleural effusion is very high (98%).
3
 However, the 
strength of the criteria for rejection of transudative 
effusion is low.
4
 Roth et al showed that 28% of patients 
with pleural effusion due to heart failure, based on the 
criteria of Light, mistakenly placed in the exudative 
liquids. The problem is aggravated when this wrong 
classification, leading to use of costly and invasive 
diagnostic methods. Therefore, a non-invasive and low-
cost strategy to differentiate effusion caused by heart 
failure would be useful.
5
 To solve this problem, Burgess 
et al. suggested using of Serum- pleural fluid albumin 
gradient.
6
 Romero-candeira et al suggested the serum-
pleural fluid protein gradient. However, the false 
diagnosis rates of albumin and protein gradient methods 
are 10% and 16%, respectively (transudative liquids 
mistakenly diagnosed as exudative).
4
 The levels of 
plasma BNP and NT-proBNP are used in the diagnosis 
and treatment of heart failure as suitable biomarkers. 
BNP is a vasoactive neurohormonal ventricular that 
secreted by myocytes in response to increased pressure 
load and heart volume. This hormone is aprohormones 
called Pro BNP that first is synthesized as a 108 amino 
acid and is divided into two parts at secretion time of pro 
BNP, on partthat is biologically active called BNP and 
the second part is disabled and called NT-proBNP. BNP 
causes to diuresis, vasodilation and reduction of rennin 
and aldosterone secretion. NT-proBNP has higher half-
life compared to BNP (120 minutes vs. 20 minutes) and 
therefore has a higher plasma concentration. NT-proBNP 
is removed from plasma, possibly by renal excretion or 
other unknown mechanisms. BNP disappears by 
Natriuretic peptide clearance receptor and metabolic 
degradation by proteolytic enzymes.
7
 In the study of 
Porcel et al. the NT-proBNP level in heart disease 
patients was significantly higher than other patients. They 
reported the sensitivity and specificity of this test for the 
diagnosis of heart failure were 91% and 93%, 
respectively.
8
 In the study of Gegenhuber et al 48.4% of 
patients were transudate and 51.6% were exudate. In their 
study, the diagnostic accuracy of plasma BNP in 
diagnosis of cardiac effusion was 93%.
9
 Tomcsanyi et al 
measured the serum and pleural NT-proBNP levels. The 
relatively high and significant levels of NT-proBNP were 
found in blood serum and pleural fluid of patients with 
cardiac effusion. They suggested a Cutoff point of 599-
1454 ng/l to determine heart Transudates.
10
 Koldtz et al 
reported that the cutoff point of 4000 ng/l for NT-
proBNP level of pleural fluid and serum.
7
 This study 
aimed to investigate the diagnostic accuracy N-terminal 
pro brain natriuretic peptide titration in pleural fluid with 
cardiac origin. 
METHODS 
This descriptive and analytical study research was carried 
out in Imam Khomeini Hospital in Ardabil. The study 
population of patients had manifestation of dyspnea and 
pleural effusion. The sample size was 21 patients with 
pleural effusion with unknown cause that referred to 
Imam Khomeini Hospital (Sep-2013 to Sep-2014). 
Inclusion criterion was diagnosis of pleural effusion and 
exclusion criteria included patients' reluctance to 
participate in the study, patients who eventually had two 
or more causes for pleural effusion, existence of blood 
fluid or infection during tap, and patients with unknown 
reasons for effusion. Patients with unilateral or bilateral 
pleural effusion that are referred by various complaints 
were selected. They considered as new cases and had no 
previous diagnosis. The chest radiography was done after 
taking a thorough history and physical examination. All 
patients were undergone to echocardiography (by one 
person). Then, pleural fluid was tapped and the following 
parameters were determined in the fluid: LDH, protein, 
albumin, cell differentiation and cell cytology for 
malignant cells, ADA, smear for AFB, and smear and 
culture of gram. In the case of heart disease, if any of the 
following cases were exists, cardiac origin for effusions 
were considered: LVEF≤40%, severe valve disease Grade 
II-III, or severe left ventricular diastolic dysfunction. Due 
to lack of feasibility, investigation of the drug or other 
accompanying disease was ignored. Blood samples and 
pleura were taken at the same time and after 12 hours of 
fasting. The samples were collected in tubes without 
additives. Exudative fluidswere followed with invasive 
procedures until the time of diagnosis and our choice for 
pleural biopsy was thoracoscopy biopsy. The criteria for 
diagnosis of malignant pleural effusion were observation 
of malignant cells liquid cytology, biopsy of in pleural, or 
lung mass biopsy. The criteria for diagnosing 
parapneumonic effusions were clinical or radiological 
diagnosis, acute parapneumonia, or positive result of 
bacterial culture in pleural fluid. The levels of NT-
proBNP were all collected pleural fluids and serum (by 
Electro chemiluminescence immunoassay). The results of 
all analysis were analyzed with statistical software, SPSS 
v16 using Chi-square, T-test and descriptive methods. 
The significance level for all tests was 0.05. In order to 
uphold the principles of medical ethics information will 
be kept confidential and results were reported 
anonymously. 
RESULTS 
The mean age of patients in this study was 65±18.01 
years. 52.4% of patients were female and 47.6% were 
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male. Frequency distribution of disease among 
participants was shown in Table 1. The most common 
diagnosis among patients belonged to CHF (33.3%) and 
the lowest frequency observed for hydatid (4.76%). 
Table 1: Frequency of participant based on final 
diagnosis. 
Variable Frequency (%) 
CHF 7 (33.3) 
TB 6 (28.5) 
Malignancy 4 (19.4) 
Hydatid 1 (4.76) 
Without diagnosis 3 (14.4) 
In our study, 66.7% had exudative pleural fluid and 
33.3% had transudative fluid. Results of 
Echocardiography showed that 72% of patients had 
normal ejection fraction (≥40) and 28% had abnormal 
ejection fraction (˂40). The results T-test showed that 
there was significantly different between protein and 
LDH levels of the pleural transudate and exudate fluids 
but this different for serum was not significant. Exudative 
fluid had higher protein than those of transudative fluid 
(Table 2). 
Among the 8 patients with pleural effusion that biopsy 
was done for them, four person had tuberculosis, two 
person showed Malignancy, one person had hidatid and 
one person left without diagnosis. Dyspnea function class 
of patients was examined and 76.2% were settled in Class 
3. Counting white blood cell (WBC), monocytes (MN) 
and polymorphoneutrophil (PMN) were showed that 
there wereno significant differences between WBC, MN, 
and PMN in two groups of exudative and exudative 
(Table 3). 
The results of T-test showed that there was no significant 
different between NT-proBNP level of pleural fluid and 
serum in exudate and transudate liquid (Table 4). 
The results of χ² test for NT-proBNP level of serum and 
pleural based ondisease diagnosis was shown in Table 5. 
The results showed that the surface of the material in the 
examined groups is statistically significant. CHF patients 
had significantly higher NT-proBNP levels of serum and 
pleural fluid compare to other patients. 
NT-proBNP level of men was higher than women, but 
this difference was not statistically significant (Table 6). 
Table 2: Protein and LDH levels of pleural fluid and serum based on type of pleural fluid. 
Variable Group Mean±SD P value 
Serum protein 
Transudative 4.88±1.02 
0.253 
Exudative 5.53±1.26 
Pleural protein 
Transudative 1.25±0.48 
<0.001 
Exudative 3.77±1.16 
Serum LDH 
Transudative 508.42±203.38 
0.714 
Exudative 473.28±±191.11 
Pleural LDH 
Transudative 168.71±121.08 
0.011 
Exudative 405.71±204.76 
Table 3: results of T test for WBC, MN, and PMN based on type of pleural fluid. 
Variable Group Mean±SD P value 
WBC (million/ml) 
Transudative 207±151 
0.380 
Exudative 3892±1070 
MN% 
Transudative 74±28 
0.067 
Exudative 46±34 
PMN% 
Transudative 38±33 
0.346 
Exudative 25±12 
Table 4: T-test results for NT-proBNP level of pleural fluid and serum in exudate and transudate liquid. 
NTproBNP level (Pg/ml) Group Mean ±SD P value 
Serum 
Transudative 11288042±11138.92 
0.058 
Exudative 3458.13±6723.23 
Pleural fluid 
Transudative 11036.81±12413.44 
0.103 
Exudative 3572.08±6723.81 
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Table 5: Results of χ² test for NT-proBNP level of serum and pleural based on disease diagnosis. 
NT-proBNP (Pg/ml) Group Mean±SD P value 
Serum 
TB 2429.30±1979.51 
0.013 
Hydatid 11.20±0 
Malignancy 1721.68±1103.54 
CHF 11288.42±11138.92 
Without diagnosis 313.36±255.59 
Pleural fluid 
TB 2810.08±1086.39 
0.030 
Hydatid 5±0 
Malignancy 713.59±466.66 
CHF 11036.81±12413.44 
Without diagnosis 245±157.25 
Table 6: Results of NTproBNP level of pleural fluid and serum based on sex. 
NT-proBNP (Pg/ml) Gender Mean±SD P value 
Serum 
Man 7089.83±3264.53 
0.632 
Female 5139.50±3087.35 
Pleural fluid 
Man 7184.65±3615.46 
0.630 
Female 5038.21±3412.12 
 
DISCUSSION 
In this study, 33.3% of patients with CHF, 19.4 percent of 
malignancy, 28.47% of TB, 14.17% and 4.66% of 
hydatid without detection. The frequencies of disease in 
similar researches were very different. For example, 
Kolditz et al. study was conducted on 93 patients, 27% 
had heart failure, 43% malignant effusions, 16% 
parapneumonic and 14% other effusions.
7
 Han et al 
studied 240 patients and showed that 98 patients had 
effusions of cardiac, 16 patientshepatic hydrothorax, 38 
patients with malignant effusions, 40 cases Mycobacteria 
effusion and 64 patients parapneumonic.
11
 Study of 
Porcel et al. was conducted on 90 patients with pleural 
effusion and 91 patients with cardiac Noncardiac, 10 
patients with hepatic hydrothorax, 40 patients with 
malignant effusion, 15 patients with parapneumonic, 11 
patients with pleural TB and 15 patients with other 
causesof exudative.
12
 Long et al. studied 80 patients was 
performed on 20 patients with cardiac effusion, 20 
patients with pleural post-CABG, 20 patients with 
malignant effusion and 20 with parapneumonic.
13
 66.7% 
had exudative pleural effusions and 33.3% had 
transducative effusions. Among the patients that were 
under biopsy, the most common diagnosis was 
tuberculosis. In the study of Tomcsányi et al. all 14 
patients had exudative pleural effusion.
10
 From 64 studied 
patients by Gegenhuber et al. 31 patients had transudate 
and 33 person hadexudate pleural effusions.
9
 These data 
confirmed our result the rate of exudative pleural effusion 
was higher, but the rates of transudate and exudate were 
different in various study. Yorgancioglu et al reported 
that 38 cases of patients with pleural effusion were 
exudative and 7 cases were transdutive.
14
 The highest 
level of NT-proBNP in serum and pleural were observed 
in CHF patients (11288.42 and 11036.18 Pg/ml, 
respectively). Followed by TB (2810.08), malignant 
(713.59), others (245), and hidatid. There was no 
significant difference between NT-proBNP of serum and 
pleural fluid of exdutive and transdutive effusion. This 
result is in agreement with the study of Koltz et al. that 
reported the NT-proBNP level of pleural fluid and serum 
was higher in the cardiac origin effusion.
7
 Our results 
also confirmed their cutoff point for diagnosis of cardiac 
origin effusion (4000 Pg/ml). In the study of Pour 
Piranfar et al. NT-proBNP plasma levels in patients with 
heart failure was 421 Pg/ml.
15
 Tomcsányi et al observed 
that the levels of NT-proBNP in patients with CHF, 
Pg/ml 8236 and exudative patients 276 Pg/ml (p=0.0006) 
and the pleural NT-proBNP in patients with CHF, 9692 
Pg/ml and exudative patients 157 Pg/ml (p=0.0001).
10
 
Porcel et al. reported that NT-proBNP levels in heart 
patients 6931was Pg/ml, in patients with hepatic 
hydrothorax 551 Pg/ml, malignant effusions 347 pg/ml, 
TB 101 Pg/ml, parapneumonic effusion 514 Pg/ml and 
pulmonary embolism 346, therefore, the NT-proBNP 
level in heart patients was significantly higher than 
others.
8
 This research is in accordance with our study, but 
in recent study the amount of NT-proBNP in the TB 
patients was higher than malignant effusions. In the study 
of Liao et al. the level of NT-proBNP in patients with 
CHF (5390 Pg/ml) was also higher than other patients 
(P<0.001).
16
 Kolditz et al found that levels of NT-
proBNP in patients with pleural effusion heart and 
Noncardiac patients were 10427 and 947 Pg/mL, 
respectively (P<0.001) the corresponding levels for 
serum were 10791 and 989 (P<0.001).
7
 In these reports 
the level of serum and pleural effusion in CHF patients 
were higher than that of cutoff point reported by Kolditz 
et al, but Han et al. obtained lower  NT-proBNP level for 
patients with pleural effusion and heart complication 
(3310 Pg/ml) but this value was higher in heart patients 
was than others (p<0.001).
7,11
 Some other researchers 
also confirmed that that serum and pleural levels of NT-
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proBNP in patients with heart failure and exudative 
pleural effusion, significantly higher than other patients. 
Seyhan et al, Porcel et al and Bayram et al, long et al and 
Abdalla et al.
12,13,17-19
 Regarding to high cost of NT-
proBNP evaluation kits and limitation of funding for 
thesis the sample size of the study was lower than of 
some other researches. 
CONCLUSION  
The results showed that the serum and pleural NT-
proBNP in cardiac origin effusion is than any other 
disease, but no significant difference was observed 
between NT-proBNP with transudative and exudative 
pleural fluid. Measurement of pleural fluid or serum NT-
proBNP is a confident method for diagnosing cardiac and 
non cardiac effusions. 
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